Erastin: Ferroptosis Inducer for Targeting Iron-Dependent Cell Death

Executive Summary: Erastin is a small molecule that induces ferroptosis, a unique iron-dependent and caspase-independent cell death pathway, by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating VDAC function (Liu et al., 2022). It selectively kills tumor cells with KRAS, HRAS, or BRAF mutations, sparing most normal cells (APExBIO). Erastin enhances the efficacy of oncolytic virus-based immunotherapy models without directly altering anti-tumor immunity (Liu et al., 2022). APExBIO supplies Erastin (B1524) as a research-grade compound with validated purity and solubility specifications. Proper storage and solution preparation are essential for experimental reproducibility (Erastin product page).

Biological Rationale

Ferroptosis is a regulated cell death process characterized by iron dependency and lipid peroxide accumulation (Liu et al., 2022). Erastin was identified as a first-in-class small molecule that induces ferroptosis by targeting system Xc⁻ and the RAS-RAF-MEK signaling axis. Tumor cells with activating mutations in KRAS, HRAS, or BRAF show increased susceptibility to ferroptosis due to altered redox homeostasis. Unlike apoptosis, ferroptosis is independent of caspase activation and displays morphological and biochemical features distinct from other programmed cell death forms. This specificity provides an opportunity for precision targeting in cancer biology research and development of therapies for drug-resistant, RAS-mutant tumors (see detailed mechanistic contrast).

Mechanism of Action of Erastin

Erastin primarily inhibits the cystine/glutamate antiporter, system Xc⁻, composed of SLC7A11 and SLC3A2 subunits (in-depth molecular analysis). This inhibition reduces cellular cystine uptake, depleting glutathione (GSH) and impairing glutathione peroxidase 4 (GPX4) activity. Accumulation of lipid peroxides ensues, leading to iron-dependent oxidative cell death. Erastin also binds to and modulates the voltage-dependent anion channel (VDAC) on the outer mitochondrial membrane, further contributing to redox dysregulation and mitochondrial dysfunction. The dual targeting of system Xc⁻ and VDAC synergistically disrupts cellular antioxidant defenses. These mechanisms have been validated in multiple cell lines and are reproducible in engineered tumor models treated with 10 μM Erastin for 24 hours at 37°C (APExBIO datasheet).

Evidence & Benchmarks

• Erastin induces ferroptosis in hepatoma, colon, and ovarian cancer cell lines, but not melanoma cells, at concentrations of 10 μM over 24 hours (Liu et al., 2022).
• Erastin selectively kills cancer cells harboring KRAS or BRAF mutations through iron-dependent, non-apoptotic cell death (mechanistic extension).
• In vivo, Erastin alone inhibits tumor growth in hepatocellular carcinoma and colon cancer models (Liu et al., 2022).
• Combined treatment with Erastin and oncolytic vaccinia virus (OVV) yields superior tumor regression and survival benefits compared to monotherapies (Liu et al., 2022).
• Erastin does not enhance systemic or local immune activation when used alone but increases dendritic cell and CD8+ T cell activity when combined with OVV (Liu et al., 2022).
• Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming; solutions are unstable for long-term storage and should be freshly prepared (APExBIO).

Applications, Limits & Misconceptions

Erastin is a gold-standard tool for dissecting ferroptosis in cancer biology and oxidative stress studies (see reproducibility focus). It is widely used in:

• Functional validation of ferroptosis in RAS/BRAF-mutant tumor lines
• Oxidative stress and redox homeostasis assays
• Screening for combination therapies targeting ferroptosis
• Basic mechanistic studies of iron-dependent, caspase-independent cell death

Common Pitfalls or Misconceptions

• Erastin is not effective in all tumor types; melanoma cell lines may show resistance (Liu et al., 2022).
• It does not induce apoptosis or necroptosis; observed cell death is ferroptotic and iron-dependent.
• Stock solutions in DMSO are unstable for long-term storage; use freshly prepared solutions for each experiment (APExBIO).
• Systemic immune activation is not observed with Erastin monotherapy; combination with immunogenic agents is required for immunomodulatory effects.
• It is not water or ethanol soluble; improper solvent selection leads to precipitation or inactivity.

Workflow Integration & Parameters

Erastin is supplied as a solid compound (molecular weight: 547.04, formula: C30H31ClN4O4) by APExBIO (B1524). For in vitro studies, dissolve Erastin in DMSO at ≥10.92 mg/mL with gentle warming. Typical experimental conditions involve 10 μM final concentration for 24-hour treatment at 37°C in cell culture models, especially in engineered tumor cells or HT-1080 fibrosarcoma cells. Store Erastin powder at -20°C; avoid repeated freeze-thaw cycles. Solutions should be prepared fresh before use to avoid compound degradation. Integration into workflows should consider controls for cell death modality and appropriate mutant/wild-type cell lines. For further troubleshooting and advanced experimental design, see the extended protocol guide (advanced workflow protocols), which this article updates by including new combinatorial immunotherapeutic findings.

Conclusion & Outlook

Erastin is an essential research tool for studying ferroptosis and oxidative cell death in RAS/BRAF-mutant cancers. Its validated mechanism and selectivity make it a cornerstone in cancer biology and redox research workflows. The combination of Erastin with oncolytic virus immunotherapy demonstrates enhanced antitumor efficacy, opening new avenues for therapeutic development. For detailed product data, specifications, and ordering, refer to the Erastin product page (B1524) from APExBIO. Continued investigation into ferroptosis biology and drug combinations will further advance precision oncology research.